Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tick-borne encephalitis vaccine (formaldehyde-inactivated)
- Development stage
- Approved
- Lead developer
- Immuno
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tick-borne encephalitis vaccine (formaldehyde-inactivated) is a biologic vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE), a viral infection caused by the tick-borne encephalitis virus. The vaccine consists of whole TBE virus propagated in chick embryo fibroblast cells and inactivated with formaldehyde. The antigen is then purified and adsorbed onto aluminum hydroxide as an adjuvant. This process preserves the structural integrity of key viral envelope proteins necessary for inducing protective immunity while rendering the virus noninfectious[1][2][4][5]. The primary mechanism of action is induction of neutralizing antibodies against the envelope proteins of TBEV. It was originally developed by Baxter International and later acquired by Pfizer; other manufacturers include Bavarian Nordic (Encepur), IPVE and Microgen in Russia, and CIBP in China[2][6]. The main indication is prevention of tick-borne encephalitis in individuals aged 1 year or older[3][7].
- Brand names
- FSME-IMMUNTicoVacEncepur
- Other names
- formaldehyde-inactivated tick-borne encephalitis vaccineinactivated TBE vaccine
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on tick-borne encephalitis vaccine (formaldehyde-inactivated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tick-borne encephalitis vaccine (formaldehyde-inactivated).